ResultsIQ

ResultsIQ › Latest results › Krishna Institute of Medical Sciences Limited

Krishna Institute of Medical Sciences Limited Q4 FY25 results press release summary

NSE: KIMS · BSE: 543308

Results press release of 12 May 2025, summarised by AI from the filing.

KIMS Q4 FY25 total revenue ₹801 cr, up 25.7% YoY; PAT ₹106 cr; FY25 revenue ₹3,067 cr, up 22.0%.

Key takeaways

  1. Q4 revenue Total revenue ₹801 cr, a growth of 25.7% on YoY and 1.4% on QoQ basis.
  2. FY25 revenue Total revenue ₹3,067 cr, a growth of 22.0% on YoY basis.
  3. PAT PAT ₹106 cr in Q4 FY25 against ₹72 cr and ₹93 cr in Q4 FY24 and Q3 FY25 respectively.
  4. Expansion Operations commenced at Thane in April 2025; 2 units in Bangalore to open in H1 FY26.
  5. Clinical Multiple complex surgeries performed across units, including Central India's first robotic transoral surgery.

Original filing on BSE

Krishna Institute of Medical Sciences Limited Q1 FY27 results

As filed: Revenue ₹1,180 cr (+35% year on year), EBITDA ₹223 cr (+16% year on year), PAT ₹37.4 cr (−56% year on year), EBITDA margin 18.9% (−319 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹1,075 cr (+35% year on year), EBITDA ₹207 cr (+4% year on year), PAT ₹33.1 cr (−49% year on year), EBITDA margin 19.2% (−563 bps). Score 43 of 100, In line with trend. Revenue growth was well above the company's own trend; EBITDA growth was below it; profit before exceptional items growth was well below it. EBITDA margin fell 563 bps year on year. Tax rate 42%. Profit fell 8% from last quarter. Share price after the results: +3.1% in 28 days (Nifty 500: +0.3%).
  • Q3 FY26: Revenue ₹998 cr (+29% year on year), EBITDA ₹199 cr (+6% year on year), PAT ₹51.9 cr (−44% year on year), EBITDA margin 19.9% (−442 bps). Score 46 of 100, In line with trend. Revenue growth was well above the company's own trend; EBITDA growth was below it; profit growth was well below it. EBITDA margin fell 442 bps year on year. Profit fell 28% from last quarter. Share price after the results: +21.1% in 28 days (Nifty 500: −4.1%).
  • Q2 FY26: Revenue ₹961 cr (+24% year on year), EBITDA ₹204 cr (−6% year on year), PAT ₹72.0 cr (−41% year on year), EBITDA margin 21.2% (−683 bps). Score 34 of 100, Below trend. Revenue growth was above the company's own trend; EBITDA and profit growth were well below it. EBITDA margin fell 683 bps year on year. Profit fell 15% from last quarter. Revenue rose ₹184 cr on a year ago, more than the ₹125 cr it added the year before. Share price after the results: −2.3% in 28 days (Nifty 500: +1.4%).
  • Q1 FY26: Revenue ₹872 cr (+27% year on year), EBITDA ₹193 cr (+8% year on year), PAT ₹85.0 cr (−11% year on year), EBITDA margin 22.1% (−388 bps). Score 50 of 100, In line with trend. Revenue growth was well above the company's own trend; EBITDA and profit growth were below it. EBITDA margin fell 388 bps year on year. Profit fell 20% from last quarter. Revenue rose ₹184 cr on a year ago, more than the ₹82.0 cr it added the year before. Share price after the results: +0.3% in 30 days (Nifty 500: +0.1%).
  • Q4 FY25: Revenue ₹797 cr (+26% year on year), EBITDA ₹198 cr (+25% year on year), PAT ₹106 cr (+49% year on year), EBITDA margin 24.8% (−8 bps). Score 81 of 100, Above trend. Revenue and profit growth were well above the company's own trend; EBITDA growth was above it. EBITDA margin was flat year on year. Revenue rose ₹163 cr on a year ago, more than the ₹58.0 cr it added the year before. Share price after the results: +3.0% in 30 days (Nifty 500: +3.7%).
  • Q3 FY25: Revenue ₹772 cr (+27% year on year), EBITDA ₹188 cr (+28% year on year), PAT ₹93.0 cr (+21% year on year), EBITDA margin 24.4% (+9 bps). Score 82 of 100, Above trend. Revenue and EBITDA growth were well above the company's own trend; profit growth was above it. EBITDA margin was flat year on year. Profit fell 23% from last quarter.
  • Q2 FY25: Revenue ₹777 cr (+19% year on year), EBITDA ₹218 cr (+22% year on year), PAT ₹121 cr (+20% year on year), EBITDA margin 28.1% (+76 bps). Score 65 of 100, Above trend. EBITDA margin rose 76 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Krishna Institute of Medical Sciences Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.